Comparison of R-miniCHOP with R-Bendamustine (R-B) in diffuse large B-cell Lymphoma (DLBCL) in elderly and comorbid patients

被引：0
|
作者：
Hammersen, F. J. [1 ]
Ruethrich, M. M. [1 ]
Wedding, U. [2 ]
Sommer, M. [3 ]
Hochhaus, A. [1 ]
La Rosee, P. [4 ]
机构：
[1] Univ Klinikum Jena, Hamatol internist Onkol, Klin Innere Med 2, Jena, Germany
[2] Univ Klinikum Jena, Palliat Med, Klin Innere Med 2, Jena, Germany
[3] Inst Allgemeinmed Jena, Jena, Germany
[4] Schwarzwald Baar Klinikum Villingen Schwenningen, Klin Innere Med Onkol Hamatol Immunol Infektiol &, Villingen Schwenningen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P173
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [21] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [23] R-IPI as a predictor of survival in patients with diffuse large cell B-cell lymphoma (DLBCL) treated with R-chop chemotherapy
    Siddiqui, M.
    Johnston, P. B.
    Micallef, I. N.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Ristow, K.
    Witzig, T. E.
    Porrata, L. F.
    ANNALS OF ONCOLOGY, 2008, 19 : 146 - 146
  • [24] Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-Cell lymphoma (DLBCL).
    Halaas, JL
    Moskowitz, CH
    Noy, A
    Portlock, C
    Horwitz, S
    Straus, D
    O'Connor, O
    Yahalom, J
    Zelenetz, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 578S - 578S
  • [25] A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage
    Toubai, Tomomi
    Kuroda, Junya
    Suehiro, Youko
    Mishima, Yuko
    Sunami, Kazutaka
    Kato, Koji
    Uoshima, Nobuhiko
    Kumode, Takahiro
    Ota, Ai
    Mitsuki, Kaori
    Yokota, Daisuke
    Sano, Yuri
    Terui, Yasuhito
    BLOOD, 2023, 142
  • [26] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [27] R-IPI in selecting patients with diffuse large B-cell lymphoma
    Stavrikj, S. Genadieva
    Stojanoski, Z.
    Veljanovska, A. Pivkova
    Balkanov, S. Krstevska
    Georgievski, B.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S543 - S543
  • [28] Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL)
    Borchmann, P.
    Bachanova, V.
    Westin, J.
    Tam, C.
    Jaeger, U.
    McGuirk, J.
    Holte, H.
    Waller, E.
    Jaglowski, S.
    Bishop, M.
    Andreadis, C.
    Foley, S. R.
    Fleury, I.
    Teshima, T.
    Mielke, S.
    Salles, G.
    Ho, J.
    Izutsu, K.
    Maziarz, R.
    van Besein, K.
    Kersten, M. J.
    Wagner-Johnston, N.
    Kato, K.
    Corradini, P.
    Han, X.
    Agoulnik, S.
    Chu, J.
    Eldjerou, L.
    Pacaud, L.
    Schuster, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 238 - 238
  • [29] CHOP-R plus bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL)
    Leonard, J. P.
    Furman, R. R.
    Cheung, Y. K.
    Vose, J. M.
    Glynn, P. W.
    Ruan, J.
    Martin, P.
    Niesvizky, R.
    LaCasce, A.
    Chadburn, A.
    Coleman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    Assouline, Sarit
    Hertzberg, Mark
    Kim, Tae Min
    Kim, Won-Seog
    McMillan, Andrew
    Ozcan, Muhit
    Hirata, Jamie M.
    Penuel, Elicia
    Cheng, Ji
    Ku, Grace
    Flowers, Christopher R.
    BLOOD, 2018, 132
12345